Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001229175 | SCV001401613 | pathogenic | not provided | 2023-05-19 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln334*) in the HSD3B2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 39 amino acid(s) of the HSD3B2 protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with congenital adrenal hyperplasia (PMID: 22343390, 28870780). ClinVar contains an entry for this variant (Variation ID: 956384). This variant disrupts a region of the HSD3B2 protein in which other variant(s) (p.Arg335*) have been determined to be pathogenic (PMID: 18252794). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV001833981 | SCV003834672 | likely pathogenic | 3 beta-Hydroxysteroid dehydrogenase deficiency | 2021-12-01 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001833981 | SCV002094677 | pathogenic | 3 beta-Hydroxysteroid dehydrogenase deficiency | 2021-07-28 | no assertion criteria provided | clinical testing |